High-purity reagents for reliable development and cGMP production
Agilent Advanced Therapeutics supplies a portfolio of bioprocessing reagents designed to support microbial fermentation, protein processing, conjugation workflows, and large-scale GMP manufacturing. Available in research, MBG, and cGMP grades, these materials provide the purity, traceability, and performance required across development and commercial production.
Our offering includes essential reductants (DTT, DTE, TCEP), oxidants such as cGMP DHAA, fermentation activators like IPTG, and cross-linking reagents including EDAC. Produced under stringent quality controls, these reagents help ensure consistency, enable efficient processing, and strengthen regulatory readiness while supporting programs at any scale.
Multiple grades available—Research, MBG, and cGMP-grade options support early development through GMP production.
Reagents for key unit operations—Materials suitable for reduction, oxidation, activation, and conjugation steps.
cGMP manufacturing support—Produced under strict QC for regulatory alignment and reproducibility.
Consistent formulation—High batch-to-batch reliability for sensitive bioprocessing workflows.
Scalable supply options—Available from gram quantities to multi-kg lots for commercial use.
Trusted in ADC workflows—cGMP-grade TCEP and DHAA supply stability and performance for conjugation steps.
Bioprocessing Reagents
High-quality research and cGMP-grade bioprocessing reagents for reliable development and manufacturing
High-purity reagents for reliable development and cGMP production
id
features
The Advanced Therapeutics Advantage
50+ years of experience
in biopharma manufacturing
7 cGMP-aligned facilities
in U.S. and Canada are equipped for multiple modalities and projects
$1.65 billion
invested into CDMO business in 2023–2026
100+ successful audits
by pharma, biotech, and global regulatory agencies
id
benefits
Specifications
Bioprocessing Reagents
Dithiothreitol (DTT)
Industry-leading quality and reliability (Purity ≥ 99%). Reagent used for maintaining thiol groups in a reduced state during protein processing, isolation, and denaturing. Incorporated into some leading COVID-19 testing kits.
Find helpful answers to common questions as you evaluate and advance your program
What grades do your bioprocessing reagents come in?
Our portfolio includes multiple quality grades to support different development stages. Research and molecular biology (MBG) grades are well suited for early studies, assay development, or non-GMP workflows. cGMP-grade materials, including TCEP, DHAA, and select reductants, are manufactured under strict quality controls to support GMP manufacturing, regulatory filings, and commercial programs. Specifications vary by reagent.
Are these reagents suitable for microbial fermentation?
Yes, several products directly support microbial expression workflows. Reagents like IPTG (non-animal origin) are specifically used for induction in microbial fermentation processes, while others such as reductants and oxidants support downstream processing and purification. All materials are available in sizes appropriate for R&D through commercial manufacturing.
Do your cGMP-grade reagents support ADC manufacturing?
Yes, our cGMP TCEP and cGMP DHAA are widely used in ADC programs as complementary redox partners. TCEP provides stable, irreversible reduction without metal interference, while DHAA offers high stability and efficient oxidation for improved yields. Both are manufactured under strict QC for regulatory readiness.
What scale of material can you supply?
We offer flexible supply options to support early development, pilot runs, and commercial programs. Most reagents can be ordered in small research volumes or scaled to multi-kilogram quantities appropriate for GMP manufacturing and long-term production campaigns.
style
id
faqs
Browse the latest news on Advanced Therapeutics manufacturing
BIOVECTRA Is Honored with 2025 CDMO Leadership Award
BIOVECTRA, a part of Agilent Technologies Inc., proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics. The award recognizes BIOVECTRA’s performance in key areas such as quality, reliability, and technical capability.
3/6/2025
Agilent Completes Acquisition of BIOVECTRA
Agilent Technologies announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.
9/20/2024
Agilent Investing $725 Million to Expand Nucleic Acid-Based Therapeutics Manufacturing
Agilent Technologies is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market and strong demand for the company’s high-quality active pharmaceutical ingredients (APIs).
1/10/2023
id
news
Innovative sustainability in water, waste, and energy
The Frederick facility integrates sustainable practices, like closed-cell cooling towers and reverse osmosis systems that save over 16 million gallons of water annually. A solar photovoltaic array generates 500 MWh of clean energy to offset utility demand. Waste reduction initiatives include acetonitrile recovery and destruction of dilute organics.
id
sustainability
Explore ways to connect with the Advanced Therapeutics team
Have questions or need a quote? Our manufacturing experts are here to help.
Get support from experienced specialists dedicated to your program’s success.
Upcoming events
See where the Agilent Advanced Therapeutics team will be next. Explore our upcoming conferences, tradeshows, and speaking engagements, and connect with us in person.
